Anthony M. Joshua

Research interests

Publications

• Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

  European Urology · 2024 · https://doi.org/10.1016/j.eururo.2024.09.017

• [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

  The Lancet Oncology · 2024 · https://doi.org/10.1016/s1470-2045(24)00135-9

• Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00529-6

• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.22.01649

• Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00275-9

• PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00605-2

• [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00237-3

• [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00237-3

• Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

  European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.04.061

• A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial

  British Journal of Cancer · 2019 · https://doi.org/10.1038/s41416-019-0474-x

• Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903835

• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

  Annals of Oncology · 2019 · 10.1093/annonc/mdz011

• Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.0391

• Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.2477

• Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking

  Nature Nanotechnology · 2016 · https://doi.org/10.1038/nnano.2016.239

• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

  JAMA · 2016 · 10.1001/jama.2016.4059

• Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

  Genome Medicine · 2016 · https://doi.org/10.1186/s13073-016-0364-2

• Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1405095

• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

  The Lancet · 2014 · 10.1016/s0140-6736(14)60958-2

• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1305133

• Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

  Modern Pathology · 2008 · https://doi.org/10.1038/modpathol.2008.96

Current projects

No projects listed.